Sanofi: favorable data in pediatric asthma
(CercleFinance.com) - Sanofi announced on Monday that new data on Dupixent had demonstrated a "consistent" long-term safety and efficacy profile in pediatric asthma.
The results, from the extension phase of a Phase III trial, show that the drug's effect, administered as a maintenance therapy and in combination with other asthma medications, remained consistent for up to two years in children aged 6-11 years with moderate-to-severe asthma with inflammatory signature type 2.
These findings include a low rate of severe asthma attacks, with an average of 0.118-0.124 attacks per year, compared to 2.16-2.56 attacks per year at baseline in the pivotal trial.
The study also showed a sustained improvement in lung function of 9.4-12.6 percentage points from baseline to week 52.
These results were presented today in a late-breaking session at the European Respiratory Society (ERS) International Congress 2022.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The results, from the extension phase of a Phase III trial, show that the drug's effect, administered as a maintenance therapy and in combination with other asthma medications, remained consistent for up to two years in children aged 6-11 years with moderate-to-severe asthma with inflammatory signature type 2.
These findings include a low rate of severe asthma attacks, with an average of 0.118-0.124 attacks per year, compared to 2.16-2.56 attacks per year at baseline in the pivotal trial.
The study also showed a sustained improvement in lung function of 9.4-12.6 percentage points from baseline to week 52.
These results were presented today in a late-breaking session at the European Respiratory Society (ERS) International Congress 2022.
Copyright (c) 2022 CercleFinance.com. All rights reserved.